GMAB
GMAB clinical trials: GENMAB A/S
Every trial on ClinicalTrials.gov where GENMAB A/S is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 104
- Trials linked
- 72
- As lead sponsor
- 32
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GMAB on the catalyst calendar · GMAB registry changes
- Primary completion Mar 30, 2029Sponsor estimatePhase 3NCT07775287Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent...Genmab · Colorectal CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 3NCT07225270Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of...Genmab · Ovarian CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 3NCT06496178A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous...Genmab · Head and Neck Squamous Cell CarcinomaActive, not recruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2025ActualPhase 3NCT07226752A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)...Genmab · Diffuse Large B-Cell LymphomaActive, not recruitingGMABLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 3NCT07702032Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic...Genmab · Left-sided Colorectal CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT07604766An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum...Genmab · Platinum-resistant Ovarian CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 3NCT07564141Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based...Genmab · Platinum-Sensitive Ovarian CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 2NCT07539311Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersGenmab · Gastrointestinal CancersRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2029Sponsor estimatePhase 1NCT07416123A Study of GEN1106 in Participants With Solid TumorsGenmab · Solid TumorsRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 18, 2029Sponsor estimatePhase 1NCT07384715First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic...Genmab · R/R AMLRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2027Sponsor estimatePhase 2NCT07288177Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerGenmab · Non-small Cell Lung Cancer (NSCLC)RecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 3NCT07166094Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerGenmab · Endometrial CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 3NCT06635824Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer...Genmab · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCActive, not recruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2026ActualPhase 3NCT06619236Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerGenmab · Platinum-resistant Ovarian CancerActive, not recruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2026ActualPhase 1NCT06573294Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsGenmab · Advanced Malignant Solid TumorsTerminatedGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT06057038A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsGenmab · Malignant Solid TumorActive, not recruitingGMABLeadBNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Genmab · High Grade Epithelial Ovarian CancerRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 1/Phase 2NCT05201248A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With...Genmab · B-Cell Non-Hodgkin LymphomaActive, not recruitingGMABLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1/Phase 2NCT04663347Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Genmab · Diffuse Large B-Cell LymphomaActive, not recruitingGMABLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT04623541Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeGenmab · Relapsed/Refractory Chronic Lymphocytic LeukemiaActive, not recruitingGMABLeadLLYCollaboratorABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1/Phase 2NCT04542824Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R...Genmab · Diffuse Large B Cell LymphomaActive, not recruitingGMABLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 1/Phase 2NCT03625037First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaGenmab · DLBCLActive, not recruitingGMABLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2028Sponsor estimatePhase 2NCT07353957Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerGenmab · Lung Cancer - Non Small Cell SquamousWithdrawnGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Genmab · Head and Neck Squamous Cell CarcinomaActive, not recruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 1/Phase 2NCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsGenmab · Advanced/Metastatic Solid TumorsRecruitingGMABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 79 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner